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Background: Small-molecule inhibitors that can target individual kinases are 
powerful tools for use in signal transduction research. It is difficult to find such 
compounds because of the enormous number of protein kinases and the highly 
conserved nature of their catalytic domains. Recently, a novel, potent, Src family 
selective tyrosine kinase inhibitor was reported (PPl). Here, we study the 
structural basis for this inhibitor’s specificity for Src family kinases. 
Results: A single residue corresponding to lle338 (v-Src numbering; Thr338 in 
c-Src) in Src family tyrosine kinases largely controls PPl’s ability to inhibit 
protein kinases. Mutation of ile338 to a larger residue such as methionine or 
phenylalanine in v-Src makes this inhibitor less potent. Conversely, mutation of 
lle338 to alanine or glycine increases PPl ‘s potency. PPl can inhibit Ser/Thr 
kinases if the residue corresponding to lle338 in v-Src is mutated to glycine. We 
have accurately predicted several non-Src family kinases that are moderately 
GO -1 PM) inhibited by PPl, including c-Abl and the MAP kinase ~38. 
Conclusions: Our mutagenesis studies of the ATP-binding site in both tyrosine 
kinases and Ser/Thr kinases explain why PPI is a specific inhibitor of Src family 
tyrosine kinases. Determination of the structural basis of inhibitor specificity will 
aid in the design of more potent and more selective protein kinase inhibitors. 
The ability to desensitize a particular kinase to PPl inhibition of residue 338 or 
conversely to sensitize a kinase to PPl inhibition by mutation should provide a 
useful basis for chemical genetic studies of kinase signal transduction. 
Addresses: ‘Department of Chemistry and 
*Department of Molecular Biology, Princeton 
University, Princeton, NJ 08544, USA. 3Department 
of Physiology, University of California, San 
Francisco, CA 94143-0444, USA. 
*Present Address: Department of Cellular and 
Molecular Pharmacology, 80x 0450, UC San 
Francisco, San Francisco, CA 94143-0450, USA. 
Correspondence: Kevan M Shokat 
E-mail: shokat@cmp.ucsf.edu 
Key words: kinase inhibitor, modeling, PPl , 
selective, Src 
Received: 24 April 1999 
Revisions requested: 18 May 1999 
Revisions received: 24 June 1999 
Accepted: 25 June 1999 
Published: 13 August 1999 
Chemistry & Biology September 1999, 6:671-678 
http://biomednet.com/elecref/1074552100600671 
1074-5521199/$ - see front matter 
0 1999 Elsevier Science Ltd. All rights resewed. 
Introduction 
Protein kinases catalyze the transfer of the y-phosphate 
from ATP to serine, threonine, tyrosine or histidine 
residues of protein substrates. They play a central role in 
controlling many signal transduction pathways including 
those in B and T cells of the immune system and 
neurons in the brain [l-4]. In fact, all eukaryotic cells 
contain many protein kinase regulatory systems (it is 
estimated that 2% of the human genome encodes 
protein kinases [5]). Because of the enormous size of the 
protein kinase family, the tremendous redundancy and 
overlapping substrate specificities of many protein 
kinases, the dissection of kinase signaling pathways is a 
challenge to existing genetic and biochemical tech- 
niques [6]. For example, kinase gene-knockouts often 
show no phenotype because other cellular kinases com- 
pensate for the missing kinase activity [7-91. One 
approach’ that avoids the problems associated with gene 
compensation is the development of mono-specific 
small-molecule inhibitors of engineered kinases [lO,ll]. 
Such inhibitors could be used to selectively block kinase 
function in order to map pathways. Kinase inhibitors are 
also potential therapeutics, but tremendous effort is 
required to identify compounds that can selectively bind 
to one particular kinase out of the estimated 2000 highly 
homologous human protein kinases [ 1 Z-141. 
One simplifying approach is to develop ‘family-selective’ 
protein kinase inhibitors that can potently inhibit all 
highly homologous members of a protein kinase family. 
The sequence identity of the kinase catalytic domains is 
high for kinases within a family (70~85% within Src family 
members), but is smaller between families (-20% 
between c-Src and protein kinase A). One protein kinase 
family for which specific inhibitors have been reported is 
the Src family of protein kinases. The Src family of tyro- 
sine kinases contains nine members, Src, Lck, Fyn, Lyn, 
Hck, Yes, Fgr, Blk and Yrk, which are involved in lympho- 
cyte development (Lck and Fyn) [2,15], platelet activation 
(c-Src, Fyn and Lyn) [16,17], mast cell degranulation 
(Lyn, c-Src and Yes) [l&19] and many other cell func- 
tions. One reason for the intense interest in inhibitors of 
Src family kinases is their involvement in regulating 
immune cell functions. Antigen stimulation of T cells 
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results in increased enzymatic activity of Fyn [ZO]. Con- 
versely, overexpression of a catalytically inactive form of 
Fyn (Fyn (LysZ96+Glu)) in thymocytes of transgenic 
mice substantially inhibited TCR-mediated T cell activa- 
tion [Zl]. The latter genetic evidence for the essential 
role of Fyn in T cell activation has made it a particularly 
attractive drug target for development of immunosup- 
pressants with new modes of action. 
Several Src family selective inhibitors have been 
described [Z-24], including 4-amino-l-tert-butyl- 
3-(p-methylphenyl) pyrazolo[3,4-dlpyrimidine (PPl) 
[24]. PPl has gained the most widespread use because 
of its potency and ease of synthesis [25-281. Hanke et al. 
[24] showed that PPl inhibits Lck and Fyn in vitro at 
concentrations significantly lower than those required to 
inhibit non-Src family kinases ZAP-70, JAKZ and 
protein kinase A present in T cells. PPl is also active in 
cells as demonstrated by the inhibition of whole cell 
tyrosine phosphorylation and proliferation in T cells 
stimulated with anti-CD3 antibody and mitogens, as 
well as B cells [‘29]. PPl can therefore be used to dissect 
the role of the Src family component of T cell receptor 
signaling and provides a complement to other T cell sig- 
naling blockers such as FK506, cyclosporin, rapamycin 
and wortmanin [30-321. 
Two key problems remain with the use of PPl as a tool for 
deconvoluting Src family dependent cell signaling path- 
ways. First, PPl shows little specificity between Src 
family kinases and therefore cannot be used to dissect the 
role of individual Src family kinases that are coexpressed 
in a given cell (e.g. T cells, B cells, mast cells and den- 
dritic cells). Second, the assertion that PPl is truly Src 
family selective has not been rigorously tested. 
The problem of rigorously checking whether a given kinase 
inhibitor can inhibit other (‘off-target’) kinases in the organ- 
ism of interest is common to all kinase inhibitors. The 
reason for this is that not all human protein kinases have 
been identified. Furthermore, the task of expressing, puri- 
fying and assaying anything close to all human kinases 
(-2000) is an almost impossible task. New sequence homol- 
ogy based methods coupled to high-throughput screening 
for kinase inhibitors might obviate the need to screen 
against all naturally occurring protein kinases [33]. Yet 
without such structure-activity data the use of small-mol- 
ecule inhibitors in cell-signaling studies may be misleading. 
To address this problem we have identified the key binding 
site amino acid residue responsible for imparting selective 
kinase inhibition of PPl. Through systematic mutagenesis 
of Ile338 in v-Src, as well as the non-Src family kinases c- 
Abl, CaMKIIa, Cdk2 and ~38, we have found a strong cor- 
relation between PPl binding affinity and amino acid 
sidechain volume at the position corresponding to Ile338 
in v-Src. We used this sequence information to identify 
another non-Src family kinase (c-Abl) that is potently inhib- 
ited by PPl. This study shows that a large component of 
PPl selectivity results from residue 338 and that other 
protein kinases can be analyzed in the same way to reveal 
the potential for inhibition by PPl. 
Results and discussion 
Molecular modeling of PPl binding to Hck and comparison 
with kinase sequence alignments 
As reported by Hanke etal. [24] PPl is a potent inhibitor 
of Lck (IC,, = 0.005 l.tM) and Fyn (IC,, = 0.006 PM), but 
is much less potent for ZAP-70 (IC,, z 100 PM) and JAKZ 
(IC,, > 50 pM; Table 1). To date, the crystal structure of 
PPl bound to a kinase has not been solved. We therefore 
used the co-crystal structure of the Src family kinase Hck 
bound to the general kinase inhibitor quercetin and a non- 
hydrolyzable ATP analog AMP-PNP as a guide to dock 
PPl into the ATP-binding site of Hck (Figure la-d) [34]. 
From this predicted binding mode, the C3 phenyl ring is 
in close contact with the sidechain of residue Thr338. 
This proximity of the C3 phenyl ring and the Thr338 
sidechain suggested to us that this residue could be a key 
determinant for PPl binding to Src family kinases. 
The position adjacent to C3, the N4 exocyclic amine of 
PPl, has already been shown to be in close contact with 
Ile338. This binding mode was confirmed through synthe- 
sis of PPl analogs with substituents at the N4 position, 
and design of compensatory mutations (Ile338+Ala or 
Ile338+Gly) in v-Src [lo]. When a bulky group such as 
(p-tert-butyl) benzoyl is added to the N4 amine of PPl, this 
PPl analog does not inhibit wild-type Src family kinases 
(IC,, > 300 pM for wild-type v-Src and wild-type Fyn) and 
it inhibits the Ile338+Gly v-Src mutant (IC,, = 0.43 PM) 
and Thr339+Gly Fyn mutant (IC,, = 0.83 pM) potently. 
Further molecular modeling suggested that the C3 phenyl 
ring adjacent to N4 amine of PPl is also in close contact 
Table 1 
IC,, values of PPl inhibition for Lck, Fyn, ZAP-70 and JAK2 
protein tyrosine kinases. 
PPl 
Tyrosine kinase Gn WI) 
Lck 
Fyn 
ZAP-70 
JAK2 
0.005-0.001 
0.006-0.001 
>lOO 
>50 
Data taken from Hanke et a/. [241. 
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Figure 1 
(a) Predicted binding orientation of PPl (red) in the Src family tyrosine 
kinase Hck active site. The crystal structures of Hck bound to 
AMP-PNP (white) and Hck bound to quercetin (yellow) were 
superimposed according to the Hck protein backbone (purple). The 
orientation of PPl was manually docked into the kinase active site by 
minimizing the van der Waals interaction between PPl and Hck using 
the dock program of Insightll. (b-d) Proposed structural basis for the 
PPl inhibition of Src family kinases as shown by a surface 
representation of the ATP-binding pocket of the Src family tyrosine 
kinase Hck bound to PPl and the proposed effect of mutating 
Thr338APhe. (b) Hck (wt) + PPl (front view). The solvent-accessible 
surface of Hck within 5 A of PPl is shown in gray; the surface of PPl 
is shown in green. The binding orientation of PPl is the same as in (a). 
(c) Hck (wt) + PPl (back view). The portion of Hck’s surface formed 
by Thr338 is shown in red. (d) Hck (Thr338+Phe) + PPl. Model of 
the unfavorable packing of PPl into Hck (Thr338+Phe) binding site, 
showing the steric clash between the C3 phenyl ring and the 
sidechain of Phe338 (blue). 
with the residue corresponding to Ile338 in v-Src [ll]. 
These C3 modified PPl derived inhibitors were shown to 
be competitive inhibitors with respect to ATP [ll]. 
Most Ser/Thr kinases have larger hydrophobic residues 
(Met, Phe, Leu and Gln) at the position corresponding to 
Thr338 in the Src family kinases (Figure 2). From a 
simple docking analysis it appears that such large amino 
acid sidechains would sterically clash with the phenyl ring 
in PPl (Figure Id). We predicted that PPl does not 
inhibit Ser/Thr kinases because these kinases contain a 
larger residue than threonine at the position correspond- 
ing to 338 in c-Src. Sequence alignments of the nine 
members of the Src family tyrosine kinases support this 
idea in that they all have a threonine at position 338 
(Figure 2). In contrast, each of the noninhibited kinases 
reported by Hanke et al [24], ZAP-70, JAKZ and PKA, all 
have a methionine at this position (Figure 2). On the 
basis of this analysis we propose that the position corre- 
sponding to Thr338 in Hck controls the binding of PPl to 
other kinases. Non-Src family kinases that have a threo- 
nine at the position corresponding to 338 in the Src 
family, such as c-Abl, PDGFR and ~38, could also be 
potently inhibited by PPl. 
Effect of position 338 amino acid identity on PPl inhibition 
The first experimental evidence that PPl derived its 
ability to inhibit Src family kinases because this family of 
kinases shared a threonine residue at position 338 (Src 
numbering will be used throughout) came from the dis- 
covery that PPl was a 700 nM inhibitor of c-Src and yet 
was a poor (IC,, = 5 pM) inhibitor of the almost identical 
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Figure 2 
“-SZC 
c-src 
Lck 
FYn 
c-yes 
Yrk 
c-Fgr 
LYn 
(318)RHEKLVQLYAMVSE----------EPIYIVIEYMSK--GSLLDFLKGEMGKY 
(318)RHEKLVQLYAVVSE----------EPIYIVTEYMSK--GSLLDFLKGETGKY 
(296)QHQRLVRLYAVVTQ----------EPIYIITEYMEN--GSLVDFLKTPSGIK 
(319)KHDKLVQLYAVVSE----------EPIYIVTEYMNK--GSLLDFLKDGEGRA 
(325lRHDKLVPLYAVVSE----------EPIYIVTEFMSK--GSLLDFLKEGDGKY 
(31S)RHDKLVQLYAVVSE----------EPIYIVTEFMSQ--GSLLDFLKDGDGRY 
(311lRHDKLVQLYAWSE----------EPIYIVTEFMCH--GSLLDFLKNPEGQD 
(295)QHDKLVRLYAVVTRE---------EPIYIITEYMAK--GSLLDFLKSDEGGK 
+ 
Hck (318)QHDKLVKLHAVVTK----------~PIYIITSFMAK--GSLLDFLKSDEGSK 
Elk (287)QHERLVRLYAVVTR----------EPIYIVTEYMAR--GCLLDFLK~DRGSR I 
Abl (313,KHPNLVQLLGVCTRE---------PPFYIITRFMTY--GNLLDYLR~CNRQR + 
Btk (473)SHEKLVQLYGVCTKQ---------RPIFIITEYMAN--GCLLNYLREMRHR 
Csk (244lRHSNLVQLLGVIVEEK--------GGLYIVTEYMAK--GSLVDYLRSRGRSV I 
PDGFR (660,PHLNVVNLLGACTKG---------GPIY~~TRYCRY--GDLVDYLHRNKH~F 
V38 (85) GLLDVFTPARSLEEF---------NDVVLVTHLMGA---DKL~DD + I 
iAP-70 (394)DNPYIVRLIGVCQA----------EALMLVMEMAGG--GPLHKFL-VGKREE 
JAKZ (906)QHDNIVKYKGVCYSAGR-------RNLRLIMEYLPY--GSLRDYLQKHKER 
PKA (99) NFPFLVKLEFSFKDN---------SNLYMVMEYVPG--GENFSHLRRIGR 
CamK II (68) KHPNIVRLHDSISEE---------GHHYLI~DLVTG--GRLFSDIVAREY 
Cdk2 (59) NHPNIVKLLDVIHTE---------NKLYLVFEFLHQ---DLKKFMDASALTG 
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Sequence alignment of residues surrounding 
lle336 (v-Src) in Src family tyrosine kinases 
and non-.% family tyrosine and Ser/Thr 
kinases. The numbering of the starting residue 
of the sequence is listed in the parentheses 
before the first residue of each sequence. The 
residue corresponding to lle336 in v-Src is 
highlighted in yellow. +, kinases inhibited by 
PPl with IC,, < 1 FM; -, kinases with 
IC,, > 1 pM; the inhibition of the remainder of 
the kinases was not determined. 
oncogenic protein v&c. v-Src and c-Src are almost identi- 
cal in their catalytic domains (98% identical). The only 
amino acid substitution in v&c that maps to the active 
site is a Thr338+Ile substitution. As we found that PPl is 
not a potent inhibitor for v-Src (Ile338) but is potent 
against c-Src (Thr338), it suggested to us that the modest 
Thr+Ile mutation at position 338 might be essential for 
potent PPl inhibition. 
To more carefully test the relationship between 
residue 338 and PPI potency, we mutated Ile338 in v-Src 
to eight different amino acids (Phe, Met, Thr, Val, Cys, 
Ser, Ala and Gly). A truncated form of v-Src that contains 
the catalytic domain of v-Src, but no functional SH3 or 
SHZ domains (XD4) was used as the model kinase in this 
study because it can be expressed in Eschetichia co& 
whereas other Src family kinases must be expressed in 
Sf9 insect cells. The XD4 fragment was fused to glu- 
tathione S-transferase (GST), which has been shown to 
aid in expression of protein kinases in bacteria [35,36]. 
The dimeric state of GST itself does not interfere with 
protein kinase activity as the GST-fused kinase exhibits 
the same kinetic constants as v-Src without the GST 
fusion [37]. When Ile338 was mutated to larger residues 
(phenylalanine and methionine), these v-Src mutants, 
Ile338+Phe XD4 and Ile338-+Met XD4, were poorly 
inhibited by PPl (IC,, = 8 pM for both mutants). The 
percent activity of Ile338+Met and Ile338-+Phe XD4 
mutants are about 25% and 10% of that of wild-type XD4, 
respectively (Table Z), and are comparable with the activ- 
ity of Ile338+Thr mutant. It is surprising that posi- 
tion 338 can tolerate almost any sized sidechain, without 
complete loss of catalytic activity. On the basis of these 
results with v-Src, we expect that the Thr338+Phe or 
Thr338+Met mutants of c-Src could potentially be 
useful in studies where a PPl insensitive c-Src (or other 
Src family kinase) is needed. 
Is a small residue at position 338 sufficient to confer PPl 
inhibition? 
To test whether a small amino acid at position 338 is suf- 
ficient for potent PPl inhibition, we mutated Ile338 to 
threonine, serine, alanine and glycine in XD4. The IC,, 
value of Ile338-+Thr XD4 (100 nM) is 50 times lower 
than the wild-type XD4. The smaller substitution 
(Ile338-+Ser) afforded a more poorly inhibited kinase 
(IC,, = 0.4 PM), perhaps because of the hydrophilic char- 
acter of serine compared with threonine and the pre- 
dicted preference of the C3 phenyl ring to bind in a 
hydrophobic pocket. The most potently inhibited v-Src 
mutants contained the smallest naturally occurring 
residues, alanine and glycine (IC,, = 0.005 l.tM for 
Ile338+Ala and Ile338+Gly mutants). Mutation of 
Ile338 to alanine therefore results in lOOO-fold more 
potent kinase inhibition by PPl. To test the generality of 
this mutation in other Src family kinases, we also 
mutated Thr339 (corresponding to Ile338 in v-Src) in 
Fyn to alanine. PPl inhibits wild-type Fyn with an IC,, 
of 0.05 yM, and is tenfold more potent against 
Thr338+Ala Fyn (IC,, = 0.005 PM). 
On the basis of the structure-activity relationships of PPl 
with v-Src and Fyn mutants at position 338, we conclude 
that PPl is Src family selective because all cellular Src 
family members have a threonine at position 338. Based on 
this analysis we asked if other kinases might be inhibited 
by PPl that have not been reported. We reasoned that PPl 
might effectively (I& < 1.0 pM) inhibit non-Src family 
tyrosine kinases that have a threonine at the position corre- 
sponding to 338 in c-Src. The tyrosine kinase c-Abl has a 
threonine at position 334 (corresponding to 338 in v-Src; 
Figure 2). We used a truncated c-Abl containing only the 
intact SHZ and SHl domains that is active when expressed 
in E. coli [38] and determined that PPl inhibits the non-Src 
family kinase, c-Abl, with an IC,, of 0.3 PM. Compared 
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with the Ile338+Thr v-Src mutant (IC,, = 0.1 l.tM) and 
wild-type Fyn (IC,, = 0.05 PM), PPl is only threefold less 
potent against the non-& family kinase c-Abl. The 
finding that a non-Src family kinase, c-Abl (50% identical 
to Src family kinases) can be inhibited by PPl, purely 
based on a sequence alignment comparison of one residue 
in the kinase binding site, confirms that residue 338 is 
essential for PPl binding to protein kinases. Furthermore, 
PPl may exhibit similar binding affinities for kinases with 
very divergent sequences from the Src family yet which 
contain a threonine or serine at the position corresponding 
to position 338 in c-Src (such as PDGFRcx&P, c-kit, Csk 
and ~38; Figure 2). 
Mutation of position 338 to alanine or glycine to sensitize 
Ser/Thr kinases to PPl inhibition 
To test the possibility that PPl could inhibit members of 
the Ser/Thr kinase family of enzymes if they contained a 
small residue at position 338 we mutated several highly 
divergent kinases to contain an alanine or glycine at this 
position. The Ser/Thr kinases in general have a large 
hydrophobic residue at the site corresponding to posi- 
tion 338 in c-Src. This fact suggests that PPl will not be a 
very effective inhibitor of these kinases. Furthermore, 
there may be other amino acid differences responsible for 
poor inhibition by PPl. We tested this using the Ser/Thr 
kinase Caz+/calmodulin dependent kinaseIIa (CamKIIa) 
and cyclin-dependent kinase 2 (Cdk2). CamKII regulates 
diverse cellular processes, including neurotransmitter 
release, muscle contraction, gene expression and cell pro- 
liferation [39]. CdkZ is an important regulator of the timing 
and co-ordination of eukaryotic cell-cycle events [40]. Both 
CamKIItx and Cdk2 have a phenylalanine at the position 
(Phe89 in CamKIIa and Phe80 in Cdk2) corresponding to 
Ile338 in v-Src. We expressed CamKIIcr as a GST fusion 
protein in E. coli and expressed Cdk2 in insect cells. PPl 
shows very poor inhibition of wild-type CamKIIa 
(IC,, = 60 PM) and wild-type Cdk2 (IC,, = 50 PM) as pre- 
dicted on the basis of the requirement for a small 
sidechain at position 338. When Phe89 is mutated to 
alanine, the Phe89+Ala CamKIIa possessed an 
IC,, = 10 l.tM for PPl. When Phe89 is further mutated to 
glycine, the mutant displays an inhibition IC,, = 0.5 PM, 
only S-lo-fold lower than inhibition of wild-type Src 
family kinases. The Phe80+Gly Cdk2 mutant is even 
more potently inhibited (IC,, = 0.16 yM), representing a 
> 300-fold improvement in PPl inhibition. 
Although most Ser/Thr kinases have a larger residue than 
threonine at the position corresponding to Ile338 in v-Src, 
a mitogen-activated protein kinase (MAPK), ~38, contains 
a threonine at this position (Thr106). Thr106 in ~38 has 
already been shown to control the sensitivity of a MAP 
kinase inhibitor SB203580 [41-43]. SB203580 potently 
inhibits MAP kinases that have a threonine at position 106 
such as ~38, and poorly inhibits those with a residue larger 
Table 2 
IC,, values of PPl inhibition for XD4, Fyn, Abl, CamKII, Cdk2 
wild-type and mutant kinases. 
Kinase 
o/, Activity 
IC,, (PM) (relative to wild type) 
Tyrosine kinase 
GST-XD4 (lle338-1Phe) 
GST-XD4 (lle338+Met) 
GST-XD4 (wt) 
GST-XD4 (lle338+Thr) 
GST-XD4 (lle338-+Val) 
GST-XD4 (lle338-+Cys) 
GST-XD4 (lle338+Ser) 
GST-XD4 (lle338-+Ala) 
GST-XD4 (lle338-+Gly) 
GST-Fyn (wt) 
GST-Fyn (Thr339-+Ala) 
GST-Abl (wt) 
GST-Abl (Thr334+Ala) 
SerIThr kinase 
GST-CamKII (wt) 
GST-CamKII (PheBO+Ala) 
GST-CamKII (PheBO+Gly) 
Cdk2 (wt) 
CdkP (PheBO+Gly) 
P38 (wt) 
P38 (Thrl06+Ala) 
P38 (Thrl 06tGly) 
8It2 10 
8f2 25 
5fl 100 
0.1 f 0.02 30 
0.1 +- 0.02 60 
0.07 + 0.02 70 
0.4 f 0.05 60 
0.005 Ii 0.002 50 
0.005 + 0.002 40 
0.05 f 0.02 100 
0.005 * 0.002 30 
0.3 + 0.03 100 
0.03 f 0.005 30 
60flO 
lOf2 
0.5 f 0.1 
50flO 
0.16 f 0.03 
0.82 f 0.2 
0.027 + 0.005 
0.026 f 0.005 
100 
90 
60 
100 
90 
100 
100 
100 
than threonine at the corresponding position such as ~38~ 
and ~386. On the basis of our molecular modeling of Src 
family kinase Hck inhibition by PPl and a sequence align- 
ment, PPl should inhibit wild-type ~38 potently. The ~38 
kinase was expressed in E. coL [44] and the IC,, value for 
PPl was determined. Indeed compared with wild-type 
CamKIIa (IC,, = 60 PM) and CdkZ (IC,, = 50 l.tM), PPl 
inhibits wild-type ~38 more potently (IC,, = 0.82 PM). 
Furthermore, when the Thrl06 in ~38 was mutated to 
alanine or glycine, both ThrlOb+Ala and Thrl06-+Gly 
have an IC,, of -0.025 PM. 
Although Ser/Thr kinases share less than 20% sequence 
identity with tyrosine kinases throughout the catalytic 
domains, they share high homology in the region directly 
surrounding the ATP-binding site, where the ATP-com- 
petitive inhibitors bind. This is most clearly demonstrated 
by the bis-indolemaleimide natural product staurosporine 
which is a potent (IC,, -10 nm) but nonselective protein 
kinase inhibitor [45]. Similarly, the flavone, quercetin is a 
general tyrosine kinase inhibitor (IC,, -24 PM) that also 
inhibits protein kinase C (IC,, -31 yM) [46]. For selective 
kinase inhibitors such as PPl, it is important to determine 
the residues that control binding to different kinases and 
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to determine whether the sequence determinants are 
highly context dependent. Mutagenesis of homologous 
residues in widely varying kinases might provide a way to 
determine these rules without the need to clone and 
express each member of the kinase superfamily. Clearly, 
more residues in addition to position corresponding to 
He338 in v-&c contribute to PPl binding. These features 
could be uncovered by saturation mutagenesis of the 
active-site residues as well as determination of the crystal 
structure of PPl bound to a Src family kinase. 
Significance 
kinases using molecular modeling and seauence analvsis. 
Protein kinases play a central role in signal transduction 
cascades. The huge number, the tremendous redun- 
dancy and overlapping substrate specificity of protein 
kinases make the dissection of kinase signaling pathways 
a challenge to existing genetic and biochemical tech- 
niques. Highly selective small-molecule inhibitors of 
protein kinases are useful probes in deconvoluting the 
complex kinase signaling pathways, as well as being 
potentially therapeutic. Despite their value, highly spe- 
cific kinase inhibitors have proven very difficult to obtain 
1471. Here, we have studied a potent Src family selective 
kinase inhibitor, PPl, and identified a single residue that 
controls the ability of PPl to potently inhibit protein 
was made using primer 1, 2, 3 and 4 with GST-XD4 plasmid as the 
template. In the first PCR, primer 1 and primer 4 were used to produce 
pVLCDK2NHA into pFBH6 vector of Sf9 insect cell expression system 
one fragment and primer 2 and primer 4 were used to produce another 
fragment, In the second round of PCR, these two fragments were 
annealed and extended to form the full-length GST-XD4 (1336F) gene. 
The PCR products were digested with BamHl and EcoRl and ligated 
into similarly digested pGEX-KT. The resultant plasmid was trans- 
formed into the f. co/i strain DH5o. GST-XD4 (lle338-+Met, 
lle338+Thr, lle338+Val, lle338+Cys, lle338+Ser, lle338+Ala and 
lle338+Gly) were made in the same way except for use of corre- 
sponding internal primers (5 and 6 for lle338-+Met, 7 and 8 for 
lle338+Thr, 9 and 10 for lle336+Val, 11 and 12 for lle338+Cys, 13 
and 14 for lle338+Ser, 15 and 16 for lle338+Ala, 17 and 18 for 
lle338+Gly). The GST-Abl (containing SH2 and SHl domains) was 
from Y.J. Wang’s lab (Department of Biology and Center for Molecular 
Genetics, UC at San Diego). GST-Abl (T334A) was constructed in the 
same way as GST-XD4 mutants except that the primers used were T- 
120Al: (5’CTACATAATCGCTGAGrrCATG) and T-l 20A2: (5’~CA- 
TGAACTCAGCGATTATGTAG). Wild-type CamKIlo was cloned into 
the pGEX-4T-1 vector from pBluscript CamKllcx plasmid with the fol- 
lowing primers: primer camk-1 : (5’~CCCGGATCCATGGCTACCAT- 
CACCTGCAC). Primer camk-2: (5’~CCCGAATCTCAATGCGG- 
CAGGACGGAGG). Primer camk-1 contains a BamHl site and primer 
camk-2 contains an EcoRl site. CamKIlo mutants were made using 
QuickChange site-directed mutagenesis kit (Strategene) according to 
the manufacturer’s instruction. The primers used to make CamKIlo 
(Phe89+Ala) were: (5’~CCACTACCTTATCGGCGATCTGGTTACT- 
GG) and (5’CCAGTAACCAGATCGCCGATAAGGTAGTGG). The 
primers used to make CamKIlo (Phe89-+Gly) were: (5’sCCACTACCT- 
TATCGCCGATCTGGTTACTGG) and (5’~CCAGTAACCAGATCGG- 
CGATAAGGTAGTGG). The CdkP ORF was cloned from plasmid 
The amino acid corresponding to Thr338 in c-Src is in and expressed and purified as described previously [49]. The primers 
close contact with the C3 phenyl ring of PPl. Kinases used to make Phe80+Gly Cdk2 were: (5’-GATCTTGGTGCAGGAA- 
with residues larger than threonine at this position do 
TTCACCAACCAGGTAGAG) and (5’~CTCTACCTGGTTGGTGAATT- 
CCTGCACCAAGATC). The cDNA encoding 6-His p38 was gener- 
not bind PPl due to a steric clash with this residue. ously provided by M.H. Cobb (University of Texas Southwestern 
Mutation of the homologous residue to alanine or glycine Medical Center) in a pT7-5 construct. The Thrl06+Ala and 
in distantly related kinases such as CamKIIa and CDK2 Thrl06+Gly p38 mutants were generated by QuickChange 
result in potent inhibition of these kinases by PPl. 
site-directed mutagenesis kit (Stratagene) on the pT7-5 construct 
according to the manufacturer’s instruction with the following primers: 
Understanding the structural basis of inhibitor specificity 5’-CCCCCATGAGATGGGCCACCAGGTACAC-3’, 5’sGTGTACCT- 
will help us to design more potent and more selective GGTGGCCCATCTCATGGGGGC-3’ (Thrl06+Ala) and 5’-GCCCC- 
protein kinase inhibitors. CATGAGATGGCCCACCAGGTACACGTC-3’, 5’-GACGTGTACCT- 
GGTGGGCCATCTCATGGGGGC-3’ (Thrl06+Gly). All mutants 
Materials and methods 
Mutagenesis, protein expression and sequence comparison 
Overlap extension PCR was used to make GST-XD4 mutants [48]. F’fu 
polymerase (Stragene) was used according to the manufacturer’s 
instructions. Eighteen synthetic oligonucleotides were used to gener- 
ate GST-XD4 and GST-Fyn mutant kinases: primer 1 (5’-TTGGATC- 
CATGGGGAGTAGCAAGAGCAAG), primer 2 (5’-TTTGAATTCCTA- 
CTCAGCGACCTCCAACAC), primer 3 (S’CTACATCGTCTTTGAG- 
TACATGAG), primer 4 (5’7CTCATGTACTCAAAGACGATGTAG), 
primer 5 (5’~CTACATCGTCATGGAGTACATGAG), primer 6 (5’~CTC- 
ATGTACTCCATGACGATGTAG), primer 7 (5’sCTACATCGTCACTG- 
AGTACATGAG), primer 8 (5’~CTCATGTACTCAGTGACGATGTAG), 
primer 9 (5’~CTACATCGTCGTTGAGTACATGAG), primer 10 (5’~CT- 
CATGTACTCAACGACGATGTAG), primer 11 (5’~CTACATCGTCTG- 
CGAGTACATGAG), primer 12 (5’~CTCATGTACTCGCAGACGATG- 
TAG), primer 13 (5’~CTACATCGTCAGCGAGTACATGAG), primer 14 
(5’~CTCATGTACTCGCTGACGATGTAG), primer 15 (B’CTACATCG- 
TCGCTGAGTACATGAG), primer 16 (5’~CTCATGTACTCAGCGA- 
CGATGTAG), primer 17 (5’~CTACATCGTCGGGGAGTACATGAG), 
primer 18(5’-CTCATGTACTCCCCGACGATGTAG). Primer 1 includes 
a BamHl cloning site and primer 2 has an EcoRl cloning site. Primer 3 
and Primer 4 contain the lle338-+Phe mutation. Primers 5-l 8 contain 
the lle338 to other mutations (see below). GST-XD4 (lle338dPhe) 
were sequenced over the entire coding region- (oligonucleotide 
sequencing and synthesis facility, Princeton University). Construction 
of GST-Fyn (wt) and GST-Fyn (Thr339dAla) were described previ- 
ously [50]. Expression and purification of v-Src, Abl and CamKIlo wild- 
type and mutant kinases were carried out in DH5cx as described by Xu 
et a/. [36] with the exception that the cells were stored at 4% 
overnight before centrifugation and lysis by French press (overnight 
storage is essential for producing highly active kinases). Expression 
and purification of p38 wild-type and mutant kinases were carried out 
in BL21 (DE3) pLysS E. co/i (Stratagene) as previously described by 
Khokhlatchev et a/. [44]. 
In vitro kinase assays 
General. In vitro kinase peptide assays were carried out in the pres- 
ence of (2 pCi) 10 nM [y3*P] ATP (6000 Ci/mmol, NEN) in 30 pl. 
(Typical kinase assays used to measure inhibitor IC,, values utilize 
lo-15pM [YELP] ATP [51]. Under such conditions it is difficult to 
compare IC,, values for mutant kinases which have different K, values 
for ATP {IC,, = K, (1 + [ATPl/K,, ATp ) We used a low concentration of 
[r.32P] ATP (10 nM) such that IC,, values determined would not be 
greatly influenced by the different K, values for different protein 
kinases and mutants, typically 1 O-l 00 pM for most wild-type kinases 
and 70-500 pM for the mutant kinases described here 1501). Reaction 
mixtures (25 pl) were spotted onto a phosphocellulose disk, immersed 
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in 1 Oo/, HOAc, and washed with 0.5% HsPO,, once with 20 ml of 
acetone, followed by scintillation counting with a Beckman liquid scin- 
tillation counter. IC,, values for PPl were determined by measuring the 
counts per minute (cpm) of 32P transferred to a phosphoacceptor sub- 
strate (given below). The transfer of 32P was measured by standard 
scintillation counting. IC,, is defined to be the concentration of inhibitor 
at which the cpm was 50% of the control (no inhibitor) disk. When the 
IC,, fell between two measured concentrations, it was calculated 
based on the assumption of an inversely proportional relationship 
between inhibitor concentration and cpm between the two data points. 
The percent activity (Table 2, last column) was determined by simulta- 
neous purification of the wild-type and the mutant kinases. The percent 
activity of mutant kinase relative to the wild-type kinase was reported as 
a ratio of vs [cpm in the presence of mutant kinase]/ v. [cpm in the 
presence of wild type kinasel, under the assay conditions for each 
kinase described above, in the absence of PPl 
XD4 and Fyn assays. Determination of IC,, values for wild-type and 
mutant forms of XD4 was described previously [lo]. Briefly, various 
concentrations of PPl were incubated with 50 mM Tris (pH E.O), 
10 mM MgCI,, 1.6 mM glutathione, 1 mglml of BSA, 0.1 mg/ml IYGE- 
FKKK (optimal SrclFyn substrate), 3.3% DMSO and 0.1-50 nM 
GST-XD4 or GST-Fyn. It was confirmed that active GST-XD4 or 
GST-Fyn was present at very low concentrations (compared to PPl). 
We verified that PPl IC,, values remained constant over a 25-fold 
range in kinase concentration bracketing the standard assay conditions 
for the most potently inhibited mutants. 
Abl assay. Various concentrations of PPl were incubated with 50 mM 
Tris (pH 8.0), 10 mM MgCI,, 1.6 mM glutathione, 1 mg/ml of BSA, 
0.1 mgiml EAIYAAPFAKKK (optimal Abl substrate), 3.30/o DMSO, and 
0.1-50 nM of GST-Abl. It was confirmed that active GST-Abl was 
present at very low concentrations (compared with PPl, see above). 
Cdk2 assay. Various concentrations of PPl were incubated with 
50 mM Tris (pH 8.0), 10 mM MgCI,, 1 mglml of BSA, 0.3 mglml 
Histone III-S, 3.3% DMSO, and 15 nM of CDK2/CyclinA. 
CamK//a assay. The CamKlla assay kit was purchased from Upstate 
Biotechnology. Various concentrations of PPl were incubated with 
15 mM MOPS (pH 7.2) 18 mM P-glycerol phosphate, 0.75 mM 
sodium orthovanadate, 0.75 mM dithiothreitol, 0.75 mM CaCI, 20 mM 
MgCI,, 0.5 PM protein kinase A inhibitor peptide, 0.5 pM protein kinase 
C inhibitor peptide, 125 PM auto Camtide II (KKALRRQETVDAL), 
10 uglml Calmodulin, 0.05 FM CamKIlo for 20 min. 
~38 assay. Various concentrations of PPl were incubated with 50 mM 
Tris (pH 8.0), 10 mM MgCI,, 1 mg/ml of BSA, 0.25 mM imidazole, 
0.3 mglml myelin basic protein, 3.3% DMSO, and 0.1 nM of p38 MAPK. 
Note added in proof 
After this manuscript was submitted, two papers describing the crystal 
structures of PPl bound to Hck [52] and Lck [531 have appeared. 
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